Clinical Trials Logo

Osteosarcoma clinical trials

View clinical trials related to Osteosarcoma.

Filter by:

NCT ID: NCT05642455 Recruiting - Neuroblastoma Clinical Trials

SPEARHEAD-3 Pediatric Study

Start date: September 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A*02 eligible and MAGE-A4 positive subjects aged 2-21 years of age with advanced cancers

NCT ID: NCT05621668 Recruiting - Soft Tissue Sarcoma Clinical Trials

A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

Start date: September 8, 2023
Phase: Phase 1
Study type: Interventional

To find a recommended dose of attIL2-T cell therapy that can be given to patients with soft tissue or bone sarcomas and to see if it can help to control the disease.

NCT ID: NCT05590572 Not yet recruiting - Osteosarcoma Clinical Trials

A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma

Start date: January 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2 study evaluating safety, tolerability, and efficacy of Sulfatinib in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed osteosarcoma ( combination Sulfatinib).

NCT ID: NCT05588648 Recruiting - Osteosarcoma Clinical Trials

Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

Start date: March 31, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

MP-VAC-209 is a Phase I/II, open label, single arm, multi-center study to assess safety, tolerability, and antitumor activity of vactosertib as a single agent in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. Vactosertib is given orally, twice a day, to people 14 years of age and older who meet the criteria for study enrollment.

NCT ID: NCT05558280 Suspended - Clinical trials for Osteosarcoma in Children

Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma

Start date: November 30, 2023
Phase: Phase 2
Study type: Interventional

Limited progress has been made in identifying novel targets that may be therapeutic for Osteosarcoma(OS) and there remains an urgent need for the development of new agents that are effective in improving survival. From this perspective, repurposing already proven targets in other tumors may offer new opportunities for OS in children and young adults. Anecdotal evidence of anti-GD2 therapy exists in OS from prior Phase 1 trials that included patients with OS.

NCT ID: NCT05535283 Not yet recruiting - Osteosarcoma Clinical Trials

Assessing Clinical Trial Experiences of Patients With Osteosarcoma

Start date: October 2024
Phase:
Study type: Observational

Clinical study participation has historically been heavily biased toward specific demographics. Several people will be invited to enroll in this study so that it may collect a variety of data about osteosarcoma clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal. People with osteosarcoma who are invited to take part in medical research will benefit from the analysis of the data.

NCT ID: NCT05515068 Not yet recruiting - Osteosarcoma Clinical Trials

Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas

COSS-Registry
Start date: September 2022
Phase:
Study type: Observational [Patient Registry]

The Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas (COSS-Registry) is a non-interventional, multicentric, international, clinical and epidemiologic patient registry. The COSS-Registry collects key data on osteosarcomas or biologically related bone sarcomas. With that data collection we want to gain new scientific insights and results about this tumor disease, prognosis, surveillance and long-term effects. Besides the data collection we would also like to foster the collection of biomaterial (tumor specimen and blood samples) for scientific research. The stored material will be used to perform cell and molecular biological analyses to identify the causes of osteosarcoma, the prognosis and possible new treatment options. As a starting point the donated biomaterial of registered patients will be analyzed firstly for the presence of a tumor predisposition by germline mutations. In case of detected genetic variations that are related to the tumor disease and which may affect the patient's health and follow-up care (because of the potentially increased risk of developing other malignant tumors), affected patients will be informed and referred to genetic counseling. Registry patients will be asked at the time of diagnosis if they wish to be informed about germline variants detected as part of the study procedures.

NCT ID: NCT05427513 Recruiting - Clinical trials for Blood Loss, Surgical

Efficacy of Tranexamic Acid in Preventing Post Operative Blood Loss in Bone Sarcoma Patient

Start date: April 6, 2022
Phase: Early Phase 1
Study type: Interventional

investigator will see the efficacy of tranexamic acid in limb salvage surgery patients which will prevent blood loss and help in conservation of blood products.

NCT ID: NCT05397522 Not yet recruiting - Tumor Clinical Trials

The Effects of Observer Presence and Type on Patients' Perception of Exercise After Bone Tumor Resection-A Qualitative Study

Start date: August 15, 2022
Phase: N/A
Study type: Interventional

The primary aim of the study is to investigate the effects of supervised exercise, telerehabilitation and home-based exercise on patient perception in patients who have undergone bone tumor resection. The secondary aim of the study is to identify the barriers to starting exercise in these patients.

NCT ID: NCT05395741 Recruiting - Osteosarcoma Clinical Trials

Regorafenib in Patients With Refractory Primary Bone Tumors

Regbone
Start date: April 28, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of the project is to improve treatment outcomes in patients with primary malignant bone tumors, refractory to standard therapy, by increasing the availability of advanced therapy, as well as to develop treatment options using advanced molecular diagnostics for patients who have not responded to the standard therapeutic regimen, and to introduce modern diagnostics for risk stratification and for the use in molecularly targeted therapies.